Reasons for discontinuation of TNF-α blocking therapy were inefficacy (n = 40, 51%), adverse events (n = 21, 27%: infection (n = 8); allergic reaction (n = 4); diarrhea or IBD (n = 5); cardio-vascular disease (n = 2); demyelization problems (n = 1); bladder cancer (n = 1)), both inefficacy and adverse events (n = 8, 10%: recurrent infections (n = 3); allergic reaction (n = 1); diarrhea or IBD (n = 2); uveitis (n = 1); malaise (n = 1)), or other reasons (n = 10, 13%: good initial response, own choice (n = 3); pregnancy wish (n = 5); lost to follow up (n = 2)). This evidence concerns the gene TNF and uveitis.